Zhitong Finance App News, Yaojie Ankang-B (02617.HK) issued an announcement, and the “Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Biliary Malignancies” (hereinafter referred to as the Guidelines) was officially released. The innovative multi-target small molecule kinase inhibitor Jientai® (tengotinib) independently developed by the company was included in the Class II recommendation category 2A for the treatment of advanced biliary tract malignancies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.